Report Industry Investment Rating - No information provided in the content Core Views - Important news: A database for performance comparison benchmarks of public funds is coming; the scale of bond ETFs has exceeded 70 billion yuan; the MSCI index has been adjusted, with 26 Chinese stocks newly included [3] - Market review: During the week of 20251103 - 20251107, major broad - based A - share indices showed an upward trend, while most overseas indices showed a downward trend [3][17] - Fund market review: Half of the active equity funds achieved positive returns this week, with the median interval return of active equity funds at 0.19%. Cyclical and financial real - estate themed funds performed prominently [3] - ETF fund statistics: The top three ETF categories in terms of performance this week were H - share broad - based, manufacturing, and cyclical themed ETFs. There were 490 ETFs with net capital inflows and 516 with net outflows [3] - Fund market dynamics: 52 public funds had new fund manager appointments, 48 new public funds were established, 44 public funds started their initial issuance, and 56 public funds were waiting to be issued [3] - Equity fund issuance tracking: The issuance scale of equity funds this week was 21.836 billion yuan, a decrease of 1.759 billion yuan from last week. There are still 276 newly issued funds in the position - building period [3] Summary by Relevant Catalogs 1. Important News 1.1 Market Dynamics - A database for performance comparison benchmarks of public funds is coming. The draft for soliciting opinions on the operation of the benchmark element library has been issued. The benchmark library mainly includes stock indices, divided into two categories, with 69 in the first category and 72 in the second [8] - The number of newly issued funds this year has reached a new high in the past three years. As of November 3, more than 1300 new funds have been issued this year, with over 700 new stock - type funds [9] - The ETF product of Jiaoyin Schroeder Fund has been approved and is expected to start issuing in December. It is the first time in 14 years that the company has restarted the layout of the ETF product line [10][11] 1.2 Product Hotspots - The scale of bond ETFs has exceeded 70 billion yuan. As of October 31, the scale reached 70.0044 billion yuan. The scale of single - product and the management scale of some fund companies have also increased significantly [11][12] - The compilation of the China Cheng Tong Brand Value Index has been launched, aiming to guide capital to state - owned central enterprises and benchmark private enterprises with core brand advantages [12] - New pharmaceutical indices have been frequently launched, such as the China Securities Science and Technology Innovation and Entrepreneurship Innovative Drug Index and the China Securities Science and Technology Innovation and Entrepreneurship Medical Device Index [12] 1.3 Overseas/Offshore Markets - The MSCI index has been adjusted, with 69 new inclusions and 64 exclusions in the MSCI Global Standard Index. In the MSCI China Index, 26 Chinese stocks were newly included and 20 were excluded [14] - Two Brazilian ETFs were snapped up by funds. They reached their fundraising scale limits on the first day of issuance, with the confirmed ratio of Huaxia Fund's Brazilian ETF at about 11.5% and that of E Fund at about 11.8% [15][16] - Public QDII funds are gradually replenishing their positions in US stocks, which has reduced the drawdown risk of some funds during the recent adjustment of the Hong Kong stock market [17] 2. Market Review - A - share market: Major broad - based indices showed an upward trend. The Shanghai Composite Index rose 1.08% to 3997.56, the CSI 300 Index rose 0.82% to 4678.79, etc. [17] - Overseas indices: Most showed a downward trend. The Nikkei 225 index fell 4.07%, the South Korean Composite Index fell 3.74%, and the Nasdaq index fell 3.04% [17] - Industry performance: The power equipment and new energy, and steel industries led the gains. The top five industries in the CITIC First - level Industry Index were power equipment and new energy (5.10%), steel (4.57%), etc. [21] 3. Fund Market Review 3.1 Active Equity Fund Performance - In the recent week, cyclical and financial real - estate themed funds performed prominently, with average interval returns of 1.55% and 0.78% respectively. In the recent three months, technology and cyclical themed funds led, with average interval returns of 25.67% and 21.54% respectively [24] - Half of the active equity funds achieved positive returns this week, with the median interval return at 0.19%. Cyclical and financial real - estate themed funds had median interval returns of 1.62% and 1.19% respectively [27] 3.2 High - performing Fund Performance Statistics - The Galaxy Core Advantage A (011629.OF) performed outstandingly this week, with an interval return of 11.65%. The report also listed the top five funds in each industry theme [29][30] 4. ETF Fund Statistics 4.1 ETF Fund Performance - In terms of the average interval return this week, the top three ETF categories were H - share broad - based (1.77%), manufacturing (1.62%), and cyclical themed ETFs (1.48%). In the recent month, the top three were international broad - based (7.11%), cyclical (5.51%), and commodity futures themed ETFs (4.49%) [31] 4.2 ETF Fund Capital Flow Statistics - In terms of net capital inflows this week, the top categories were technology (9.242 billion yuan), pharmaceuticals (9.059 billion yuan), and financial real - estate (7.223 billion yuan). The category with the largest net outflows was A - share broad - based (18.939 billion yuan) [34] - There were 490 ETFs with net capital inflows and 516 with net outflows. The top three ETFs with net inflows were Guotai CSI All - Index Securities Company ETF, Haifutong CSI Short - Term Financing ETF, etc. The top three with net outflows were Huatai - Peregrine CSI 300 ETF, Huaxia SSE 50 ETF, etc. [37] 4.3 ETF Fund Premium and Discount Statistics - As of November 7, 2025, the top three ETFs in terms of premium rate were Huatai - Peregrine China Securities Korea Exchange China - South Korea Semiconductor ETF, Huaan Mitsubishi UFJ Nikkei 225 ETF, etc. The top three in terms of discount rate were E Fund CSI Hong Kong Stock Connect China 100 ETF, Huaxia SSE Smart - Selection Science and Technology Innovation Value 50 Strategy ETF, etc. [39] 5. Fund Market Dynamics 5.1 Fund Manager Changes - 52 public funds had new fund manager appointments, involving 46 fund managers from 35 fund management companies. The top three fund management companies in terms of the number of affected funds were Fullgoal Fund, Bosera Fund, etc. [41] - 57 public funds had fund manager departures, involving 35 fund managers from 28 fund management companies. The top three fund management companies in terms of the number of affected funds were Yongying Fund, Dacheng Fund, etc. [42] 5.2 Newly Established Funds This Week - A total of 48 new public funds were established this week, with a combined issuance share of 26.5 billion [3] 5.3 Funds with Initial Issuance This Week - 44 public funds started their initial issuance this week, with the largest number being passive index funds (14) [3] 5.4 Funds Waiting to be Issued - As of November 9, 2025, there were 56 public funds waiting to be issued [3] 5.5 Equity Fund Issuance Tracking - The issuance scale of equity funds this week was 21.836 billion yuan, a decrease of 1.759 billion yuan from last week. There are still 276 newly issued funds in the position - building period, with an estimated 29.71% having a position - building ratio of less than 5% and an estimated 82.761 billion yuan of funds yet to be invested [3]

Group 1 - The Huatai Securities Investment Summit held on November 5-6 emphasized optimism towards the revaluation of Chinese assets and the "old economy" [1] - The summit gathered nearly 3,000 professional investors and institutional clients from various sectors including public funds, private equity, banks, insurance, and listed companies [1] Group 2 - The China Securities Index Co., Ltd. announced the launch of the China Securities Science and Technology Innovation Drug Index and the China Securities Science and Technology Innovation Medical Device Index on November 7, providing more investment options [2] - The first version of the commercial insurance innovative drug directory is set to be officially released in the first weekend of December, following negotiations involving 120 domestic and foreign companies [3] Group 3 - Hong Kong ranked fourth globally in the 2025 World Digital Competitiveness Ranking, showing significant improvements in technology and knowledge [4] - The Hong Kong government is committed to enhancing its innovation and technology strategy, aiming to attract businesses and talent to foster development [4] Group 4 - The China Securities Regulatory Commission announced the initiation of reforms for the Growth Enterprise Market to better serve the "14th Five-Year Plan" for technological innovation [5] - The market saw a notable increase in the number of active equity fund managers, surpassing 100 for the first time, indicating a growing interest in equity funds [8] Group 5 - Banks are accelerating the disposal of non-performing assets, with several banks announcing significant asset packages, which is seen as beneficial for both bank stability and support for the real economy [6] - The fund issuance market is heating up, with two "daylight funds" launched on the same day, reflecting a resurgence in new fund offerings [7] Group 6 - Berkshire Hathaway reported a 34% year-on-year increase in operating profit for Q3, driven by a surge in insurance underwriting profits [9] - The alternative investment management sector is increasingly recognizing the significance of the Chinese market, highlighting its vast scale and innovative potential [10] Group 7 - MSCI announced the results of its November index adjustments, which will take effect after the market closes on November 24, 2025 [11] - Chongqing's government introduced measures to support the high-quality development of innovative drugs, aiming for 1-3 new drug approvals annually by 2027 [12] Group 8 - The Financial Regulatory Bureau issued a notification to adjust the regulatory levels for certain administrative licenses and reporting matters, streamlining the regulatory process [13][14] - A well-known brokerage firm appointed a new chairman, reflecting confidence in management capabilities [15] Group 9 - The China Europe Fund announced a limit on large subscriptions for its small-cap growth fund, indicating a trend of limiting large investments in high-performing funds [16] - Nanjing Securities received approval for its private placement plan, while another firm terminated its fundraising efforts, highlighting the challenges in the brokerage sector [17] Group 10 - Private equity firms revealed their latest portfolio adjustments, with significant movements in technology and consumer sectors, indicating a strategic shift in investment focus [18] - The A-share market is experiencing a "slow bull" phase, with opportunities in sectors like AI, robotics, and high-end manufacturing being highlighted by private equity firms [19]

Core Points - The China Securities Index Co., Ltd. will officially launch the China Securities Innovation Drug Index and the China Securities Innovation Medical Device Index on November 7, providing more investment options for the market [1][2]. Group 1: Innovation Drug Index - The China Securities Innovation Drug Index selects listed companies involved in innovative drug research and development from the Sci-Tech Innovation Board and the Growth Enterprise Market, reflecting the overall performance of these companies [3]. - A total of 50 constituent stocks have been included in the index, such as BeiGene, Bairui Tianheng, and Kanglong Chemical [3]. - Notable stocks include: - BeiGene-U: Latest closing price of 277.50 CNY, year-to-date increase of 72.34%, and total market value of 279.45 billion CNY [4]. - Bairui Tianheng: Latest closing price of 361.50 CNY, year-to-date increase of 88.55%, and total market value of 149.25 billion CNY [4]. - Kanglong Chemical: Latest closing price of 32.25 CNY, year-to-date increase of 26.52%, and total market value of 54.40 billion CNY [4]. Group 2: Medical Device Index - The China Securities Innovation Medical Device Index selects listed companies providing medical devices, consumables, and in vitro diagnostics from the Sci-Tech Innovation Board and the Growth Enterprise Market, reflecting the overall performance of these companies [5]. - A total of 50 constituent stocks have been included in the index, such as Mindray Medical, New Industry, and Aimeike [5]. - Notable stocks include: - Mindray Medical: Latest closing price of 206.35 CNY, year-to-date decrease of 17.92%, and total market value of 250.19 billion CNY [6]. - New Industry: Latest closing price of 61.98 CNY, year-to-date decrease of 10.53%, and total market value of 48.70 billion CNY [7]. - Aimeike: Latest closing price of 152.00 CNY, year-to-date decrease of 14.30%, and total market value of 45.99 billion CNY [7]. Group 3: Market Trends - The pharmaceutical sector has attracted significant investor attention this year, particularly in the innovative drug space, which has shown remarkable performance [8]. - China's innovative drug pipeline and clinical trial projects rank among the top globally, with ongoing policy support aimed at promoting high-quality industry development [8]. - The medical device industry is also experiencing rapid growth, driven by innovation and the trend of import substitution, as well as global expansion [9].

Core Viewpoint - The announcement by China Securities Index Co., Ltd. regarding the launch of the CSI Innovation Drug Index and the CSI Medical Device Index on November 7 aims to provide a broader range of investment options in the innovative pharmaceutical and medical device sectors [1] Group 1: CSI Innovation Drug Index - The CSI Innovation Drug Index will select listed companies from the Sci-Tech Innovation Board and the ChiNext that are involved in innovative drug research and development, as well as services for pharmaceutical companies [1] - This index is designed to reflect the overall performance of listed companies in the innovative drug sector on the Sci-Tech Innovation Board and ChiNext [1] Group 2: CSI Medical Device Index - The CSI Medical Device Index will select listed companies from the Sci-Tech Innovation Board and the ChiNext that provide medical devices, consumables, and in vitro diagnostic products and services [1] - This index aims to represent the overall performance of listed companies in the medical device sector on the Sci-Tech Innovation Board and ChiNext [1]

Core Insights - The China Securities Index Co., Ltd. will officially launch the China Securities Innovation Drug Index and the China Securities Medical Device Index on November 7, providing richer investment targets for the market [1] Group 1: Innovation Drug Index - The China Securities Innovation Drug Index selects listed companies involved in innovative drug research and development, as well as those providing drug research, development, and production services from the Sci-Tech Innovation Board and the Growth Enterprise Market [4] - A total of 50 constituent stocks have been included in the index, such as BeiGene, Boli Tianheng, Kanglong Chemical, and Zhifei Biological [4] - The innovative drug sector has attracted significant investor attention this year, with China's innovative drug pipeline and clinical trial projects ranking among the top globally [4] Group 2: Medical Device Index - The China Securities Medical Device Index selects listed companies that provide medical devices, consumables, and in vitro diagnostic products and services from the Sci-Tech Innovation Board and the Growth Enterprise Market [4] - 50 constituent stocks have been included in this index, including Mindray Medical, United Imaging, New Industry, and Aimeike [4] - The domestic medical device industry is experiencing rapid development, with a positive outlook on innovation-driven import substitution and global expansion [5]

Core Viewpoint - The China Securities Index Co., Ltd. will officially launch the China Securities Innovation Drug Index and the China Securities Innovation Medical Device Index on November 7, providing a broader range of investment targets for the market [2]. Group 1: Innovation Drug Index - The China Securities Innovation Drug Index selects listed companies involved in innovative drug research and development from the Sci-Tech Innovation Board and the Growth Enterprise Market, reflecting the overall performance of these companies [2]. - A total of 50 constituent stocks have been included in the index, such as BeiGene-U, Zai Lab, and Kanglong Chemical [2]. - Notable performance includes BeiGene-U with a latest closing price of 277.50 yuan per share and a year-to-date increase of 72.34% [4]. Group 2: Medical Device Index - The China Securities Innovation Medical Device Index selects listed companies providing medical devices, consumables, and in vitro diagnostics from the Sci-Tech Innovation Board and the Growth Enterprise Market, reflecting the overall performance of the medical device sector [5]. - The index also includes 50 constituent stocks, including Mindray Medical, United Imaging, and New Industries [5]. - Mindray Medical has a latest closing price of 206.35 yuan per share, with a year-to-date decline of 17.92% [6]. Group 3: Market Trends - The pharmaceutical sector has attracted significant investor attention this year, particularly in the innovative drug space, which has shown remarkable performance [7]. - China's innovative drug pipeline and clinical trial projects rank among the top globally, with ongoing policy support aimed at promoting high-quality industry development [7]. - The medical device industry is also experiencing rapid growth, driven by innovation and the trend of import substitution, as well as global expansion opportunities [8].

Core Insights - The announcement by China Securities Index Co., Ltd. regarding the launch of the CSI Innovation Drug Index and the CSI Medical Device Index on November 7, 2025, aims to provide a broader range of investment options for the market [1]. Group 1: Index Details - The CSI Innovation Drug Index will select listed companies from the Sci-Tech Innovation Board and the ChiNext Board that are involved in innovative drug research and development, as well as those providing research, development, and production services for pharmaceutical companies [1]. - The CSI Medical Device Index will include listed companies from the same boards that offer medical devices, medical consumables, and in vitro diagnostic products and services [1]. Group 2: Market Impact - These indices are designed to reflect the overall performance of listed companies in the innovative drug and medical device sectors within the Sci-Tech Innovation Board and ChiNext Board [1].

Core Points - China Securities Index Co., Ltd. plans to launch two new indices on November 7, 2025, namely the China Securities Innovation Drug Index and the China Securities Medical Device Index, to provide additional investment options for the market [1][2]. Group 1 - The China Securities Innovation Drug Index will select listed companies from the Sci-Tech Innovation Board and the ChiNext Board that are involved in innovative drug research and related services, reflecting the overall performance of this sector [1][2]. - The China Securities Medical Device Index will select listed companies from the Sci-Tech Innovation Board and the ChiNext Board that provide medical devices and related services, reflecting the overall performance of the medical device sector [1][2].